Henlius Biotech wraps up IPO at price floor
Shanghai Henlius Biotech has settled its Hong Kong SAR listing at the bottom of the price guidance, mopping up HK$3.21bn ($410m) from the first post-earnings season IPO in the city.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: